New trial aims to outsmart drug resistance in colorectal cancer

NCT ID NCT07318389

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether matching drug combinations to a patient's tumor characteristics can better control metastatic colorectal cancer. Researchers will use blood draws, biopsies, and imaging to track how tumors resist treatment. The study enrolls 100 adults with measurable tumors and aims to check safety first.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Combination of standard chemotherapy (FOLFIRI, FOLFOX) and targeted drugs (bevacizumab, cetuximab, panitumumab, encorafenib, adagrasib, trifluridine/tipiracil, trastuzumab deruxtecan, tucatinib, sotorasib) chosen based on tumor genetics
What this could lead to: If successful, this could point toward more effective, personalized treatment plans for metastatic colorectal cancer by overcoming drug resistance.
What could go wrong: This is a very early (Phase 1) trial with only 100 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness. Side effects from multiple drug combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYNAMIC TUMOR RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYNAMIC TUMOR RESISTANCE METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.